Having received an initial investment commitment of 217 million dollars, Denali Therapeutics, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases launched its services. Among the founding investors of the company are Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund. Denali Therapeutics is based on the collaboration of […]